×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Leap Therapeutics Stock Forecast, Price & News

$1.22
+0.02 (+1.67%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.19
$1.27
50-Day Range
$0.96
$1.37
52-Week Range
$0.92
$4.17
Volume
335,645 shs
Average Volume
615,944 shs
Market Capitalization
$107.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
268.9% Upside
$4.50 Price Target
Short Interest
Bearish
15.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.87 out of 5 stars

Medical Sector

623rd out of 1,433 stocks

Pharmaceutical Preparations Industry

305th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Leap Therapeutics logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock News Headlines

Leap Therapeutics: Q4 Earnings Insights
3 Biotech Stocks That Surged in September
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Company Calendar

Last Earnings
5/13/2022
Today
7/07/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+268.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-40,590,000.00
Net Margins
-2,705.80%
Pretax Margin
-3,720.27%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$1.22 per share

Miscellaneous

Free Float
77,278,000
Market Cap
$107.75 million
Optionable
Not Optionable
Beta
0.64














Leap Therapeutics Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Leap Therapeutics stock.
View analyst ratings for Leap Therapeutics
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued 1 year price objectives for Leap Therapeutics' shares. Their LPTX stock forecasts range from $4.00 to $6.00. On average, they expect Leap Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 268.9% from the stock's current price.
View analysts' price targets for Leap Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Leap Therapeutics' stock price performed in 2022?

Leap Therapeutics' stock was trading at $3.24 at the beginning of 2022. Since then, LPTX shares have decreased by 62.3% and is now trading at $1.22.
View the best growth stocks for 2022 here
.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Leap Therapeutics
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings data on Friday, May, 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Leap Therapeutics had a negative net margin of 2,705.80% and a negative trailing twelve-month return on equity of 47.38%.
View Leap Therapeutics' earnings history
.

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director (Age 53, Pay $1.04M)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 65, Pay $693.83k)
  • Dr. Cynthia A. Sirard, Chief Medical Officer (Age 52, Pay $691.22k)
  • Mr. Mark O'Mahony, Chief Manufacturing Officer (Age 51)
  • Ms. Christine M. Granfield, VP and Head of Regulatory Affairs & Quality (Age 54)
  • Dr. Jason S. Baum Ph.D., VP & Head of Translational Medicine
  • Dr. Walter Newman, Sr. Research Fellow (Age 76)

What other stocks do shareholders of Leap Therapeutics own?

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $1.22.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $107.75 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Leap Therapeutics have?

Leap Therapeutics employs 36 workers across the globe.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for Leap Therapeutics is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.